Example: confidence
HIGHLIGHTSOFPRESCRIBINGINFORMATION ...
BSA), although embryotoxicity was observed at higher doses. 8.2 Lactation Risk Summary It is not known whether ciprofloxacin and dexamethasone are present in human milk following topical oticadministration. Published literature reports the presence of ciprofloxacin in human milk after oral administration to lactating women.
Information
Domain:
Source:
Link to this page:
Documents from same domain
HIGHLIGHTS OF PRESCRIBING INFORMATION CAR-positive …
www.novartis.usSee full prescribing information for complete boxed warning. • Cytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred in patients receiving KYMRIAH. Do not administer KYMRIAH to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with
Enrollment Application for the Novartis Patient Assistance ...
www.novartis.usVOTRIENT® (pazopanib) tablets ZOMETA® (zoledronic acid) for injection ZORTRESS® (everolimus) ZYKADIA® (ceritinib) capsules *Additional products may be available. Please check the NPAF website at www.pap.novartis.com for the …
ADAKVEO. ADAKVEO HIGHLIGHTS OF PRESCRIBING …
www.novartis.usPregnancy: May cause fetal harm. (See 17 for PATIENT COUNSELING INFORMATION and FDA-8.1) approved patient labeling. Revised: 7/2021 FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 Recommended Dosage 2.2 Preparation and Administration 2.3 Management of Infusion …
MAYZENT. treatment and if there is any change in vision ...
www.novartis.usTest patients for antibodies to varicella zoster virus (VZV) before initiating MAYZENT; VZV vaccination of antibody-negative patients is recommended prior to commencing treatment with MAYZENT [see Warnings and Precautions (5.1)]. Liver Function Tests
Instructions - Novartis United States of America
www.novartis.usI consent to receive marketing calls and texts from and on behalf of NPAF, made with an auto dialer or prerecorded voice, at the phone number(s) provided. I understand that my consent is not required or a condition of purchase. Number of messages will vary based on your program selections. Message and data rates may apply.
HIGHLIGHTS OF PRESCRIBING INFORMATION These …
www.novartis.usacute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. (1.4) ... Reports of motor vehicle accidents have been received in patients receiving Gleevec. Caution patients about driving a car or operating machinery. (5.13) Renal Toxicity. A decline in renal function may occur in patients receiving
HIGHLIGHTS OF PRESCRIBING INFORMATION These …
www.novartis.usPancreatitis and Elevated Serum Lipase: Monitor serum lipase; if elevations are accompanied by abdominal symptoms, interrupt doses and consider appropriate diagnostics to exclude pancreatitis. (5.5) Hepatotoxicity: Monitor hepatic function tests monthly or …
prescribing information for AFINITOR/AFINITOR DISPERZ ...
www.novartis.uswith sunitinib or sorafenib. (1.3) Adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. (1.4) AFINITOR and AFINITOR DISPERZ are kinase inhibitors indicated for the treatment of adult and …
COSENTYX (secukinumab) injection, for subcutaneous use o ...
www.novartis.usCOSENTYX is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation. 1.5 Enthesitis-Related Arthritis COSENTYX is indicated for the treatment of active enthesitis-related arthritis (ERA) in patients 4 years of age and older.
Novartis Patient assistance Foundation Application
www.novartis.us• Patient Section 5: We need you to read the Patient Authorization page to allow us to process your application, communicate with you and manage your enrollment. Please read, sign and date at the bottom of the Patient Application. Lastly, work with your health care provider (HCP) to complete his/her sections of the application. If you